HANGZHOU TIGERMED CO. H 1 (5HZ1) - Total Liabilities
Based on the latest financial reports, HANGZHOU TIGERMED CO. H 1 (5HZ1) has total liabilities worth €4.24 Billion EUR (≈ $4.95 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore HANGZHOU TIGERMED CO. H 1 equity growth rate to track the company's year-over-year net asset growth rate.
HANGZHOU TIGERMED CO. H 1 - Total Liabilities Trend (2021–2025)
This chart illustrates how HANGZHOU TIGERMED CO. H 1's total liabilities have evolved over time, based on quarterly financial data. See 5HZ1 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
HANGZHOU TIGERMED CO. H 1 Competitors by Total Liabilities
The table below lists competitors of HANGZHOU TIGERMED CO. H 1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Adira Dinamika Multi Finance
JK:ADMF
|
Indonesia | Rp19.82 Trillion |
|
Xinyaqiang Silicon Chemistry Co Ltd
SHG:603155
|
China | CN¥157.39 Million |
|
Peapack-Gladstone Financial
NASDAQ:PGC
|
USA | $6.87 Billion |
|
Civista Bancshares Inc
NASDAQ:CIVB
|
USA | $3.79 Billion |
|
Goldcard High-Tech Co Ltd
SHE:300349
|
China | CN¥2.70 Billion |
|
ARS Pharmaceuticals, Inc
NASDAQ:SPRY
|
USA | $213.39 Million |
|
Beijing Lanxum Tech Co
SHE:300010
|
China | CN¥640.31 Million |
|
Shenzhen Guangju Energy Co Ltd
SHE:000096
|
China | CN¥546.23 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down HANGZHOU TIGERMED CO. H 1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see HANGZHOU TIGERMED CO. H 1 (5HZ1) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HANGZHOU TIGERMED CO. H 1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HANGZHOU TIGERMED CO. H 1 (2021–2025)
The table below shows the annual total liabilities of HANGZHOU TIGERMED CO. H 1 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €4.10 Billion ≈ $4.80 Billion |
-10.94% |
| 2024-12-31 | €4.61 Billion ≈ $5.39 Billion |
-11.87% |
| 2023-12-31 | €5.23 Billion ≈ $6.11 Billion |
+9.69% |
| 2022-12-31 | €4.77 Billion ≈ $5.57 Billion |
+51.96% |
| 2021-12-31 | €3.14 Billion ≈ $3.67 Billion |
-- |
About HANGZHOU TIGERMED CO. H 1
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing … Read more